Knight Therapeutics (GUD) News Today C$5.83 +0.08 (+1.39%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock GUD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Raymond James Financial Weighs in on TSE:GUD FY2027 EarningsJune 24, 2025 | americanbankingnews.comTSE:GUD FY2027 EPS Lifted by Raymond James FinancialJune 23, 2025 | marketbeat.comTSE:GUD FY2025 EPS Lifted by Raymond James FinancialJune 21, 2025 | americanbankingnews.comTSE:GUD FY2025 EPS Increased by Raymond James FinancialJune 19, 2025 | marketbeat.comKnight Therapeutics (TSE:GUD) Shares Down 0.2% - What's Next?June 3, 2025 | marketbeat.comKnight Therapeutics (TSE:GUD) Trading Down 6.4% - Should You Sell?May 11, 2025 | marketbeat.comEarnings call transcript: Knight Therapeutics Q1 2025 beats EPS forecastMay 10, 2025 | uk.investing.comWhy this value manager likes Knight Therapeutics but is changing the channel on Warner Bros. DiscoveryMarch 28, 2025 | theglobeandmail.comAnalysts Offer Predictions for TSE:GUD Q1 EarningsMarch 28, 2025 | marketbeat.comWhat is Stifel Canada's Forecast for TSE:GUD Q2 Earnings?March 27, 2025 | marketbeat.comKnight Therapeutics (TSE:GUD) Given New C$7.45 Price Target at Stifel NicolausMarch 26, 2025 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sells C$15,750,000.00 in StockMarch 25, 2025 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 2,500,000 SharesMarch 25, 2025 | insidertrades.comResearch Analysts Issue Forecasts for TSE:GUD Q4 EarningsMarch 24, 2025 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 550,000 Shares of StockMarch 21, 2025 | marketbeat.comCollective, Knight at 52-Week Highs on NewsMarch 21, 2025 | baystreet.caSime Armoyan selling more Knight Therapeutics (GUD)March 20, 2025 | theglobeandmail.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 92,200 SharesMarch 19, 2025 | marketbeat.comKnight Therapeutics (TSE:GUD) Reaches New 12-Month High - Here's WhyMarch 19, 2025 | marketbeat.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Insider Sells 92,200 Shares of StockMarch 19, 2025 | insidertrades.comKnight Therapeutics (TSE:GUD) Raised to Strong-Buy at Research CapitlMarch 15, 2025 | marketbeat.comKnight Therapeutics price target raised to C$8 from C$7.50 at Raymond JamesMarch 12, 2025 | markets.businessinsider.comKnight Therapeutics (TSE:GUD) Stock Price Up 9.2% - Still a Buy?March 12, 2025 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Purchases 17,600 SharesMarch 6, 2025 | marketbeat.comInsider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Buys 17,600 Shares of StockMarch 6, 2025 | insidertrades.comKnight Therapeutics (TSE:GUD) Trading Up 1.4% - Here's WhyFebruary 18, 2025 | marketbeat.comKnight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for OnicitJanuary 31, 2025 | finanznachrichten.deGot $4,000? 4 Healthcare Stocks to Buy and Hold ForeverJanuary 27, 2025 | fool.caKnight Therapeutics (TSE:GUD) Trading Up 0.6% - Time to Buy?January 4, 2025 | marketbeat.comKnight Therapeutics (TSE:GUD) Trading Down 2.5% - Here's What HappenedDecember 13, 2024 | marketbeat.comSime Armoyan Purchases 90,300 Shares of Knight Therapeutics Inc. (TSE:GUD) StockNovember 16, 2024 | insidertrades.comKnight Therapeutics (TSE:GUD) Upgraded at Raymond JamesNovember 16, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Buys 90,300 SharesNovember 15, 2024 | marketbeat.comQ4 Earnings Estimate for TSE:GUD Issued By Raymond JamesNovember 15, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Buys 20,000 SharesNovember 12, 2024 | insidertrades.comStifel Canada Issues Negative Outlook for TSE:GUD EarningsNovember 11, 2024 | marketbeat.comKnight Therapeutics (GUD) Set to Announce Earnings on ThursdayNovember 1, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Trading Down 0.3% - Time to Sell?October 14, 2024 | marketbeat.comKnight Therapeutics Inc. (TSE:GUD) Insider Sime Armoyan Sells 300,000 SharesSeptember 22, 2024 | insidertrades.comKnight Therapeutics Inc. (TSE:GUD) Insider Sells C$1,839,000.00 in StockSeptember 21, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Sets New 52-Week High at $6.23September 17, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Stock Price Up 7.3%September 11, 2024 | marketbeat.comAmal Khouri Sells 5,000 Shares of Knight Therapeutics Inc. (TSE:GUD) StockAugust 21, 2024 | insidertrades.comInsider Selling: Knight Therapeutics Inc. (TSE:GUD) Senior Officer Sells 5,000 Shares of StockAugust 19, 2024 | marketbeat.comResearch Analysts Issue Forecasts for Knight Therapeutics Inc.'s FY2024 Earnings (TSE:GUD)August 15, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Upgraded at Stifel CanadaAugust 14, 2024 | marketbeat.comStifel Canada Weighs in on Knight Therapeutics Inc.'s Q3 2024 Earnings (TSE:GUD)August 14, 2024 | marketbeat.comKnight Therapeutics (TSE:GUD) Rating Increased to Buy at Stifel NicolausAugust 13, 2024 | marketbeat.comKnight Therapeutics Inc. (GUD.TO)August 12, 2024 | ca.finance.yahoo.comFY2025 EPS Estimates for Knight Therapeutics Inc. Lifted by Raymond James (TSE:GUD)August 12, 2024 | marketbeat.com Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address GUD Media Mentions By Week GUD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GUD News Sentiment▼0.940.90▲Average Medical News Sentiment GUD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GUD Articles This Week▼31▲GUD Articles Average Week Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BHC News CRON News TLRY News ACB News WEED News CPH News OGI News CRDL News RX News HLS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:GUD) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
